Telaah kritis terapi risperidone untuk perbaikan perilaku pada gangguan spectrum autistik

Article Sidebar

PDF
Published: Apr 27, 2007
DOI: https://doi.org/10.18051/UnivMed.2007.v26.39-45 Universa Medicina
Abstract Viewed: 843
PDF Downloaded: 635
Keywords:
Autistik risperidone anti psikotik perilaku

Main Article Content

Rizaldy Pinzon
SMF Saraf RSUD Dr. M.Haulussy Ambon Maluku
Lucas Meliala
Bagian Saraf Fakultas Kedokteran Universitas Gadjah Mada
Sri Sutarni
SMF Saraf RSUD Dr. M.Haulussy Ambon Maluku

Abstract

Autisme adalah sindroma klinik yang ditandai oleh gangguan interaksi sosial, hambatan komunikasi verbal, dan keterbatasan aktivitas serta minat. Sampai saat ini, tidak ada terapi untuk autisme. Pengobatan farmakologis terutama ditujukan untuk mengurangi agresivitas, perilaku obsesif kompulsif, dan perilaku melukai diri sendiri. Telaah pustaka ini menunjukkan bahwa risperidone efektif dan aman untuk terapi tantrum, agresivitas, dan perilaku melukai pada anak-anak autistik. Namun risperidon tidak dapat memperbaiki kekurang anak dalam hal interaksi sosial dan komunikasi. Diperlukan penelitian lebih lanjut untuk mengembangkan pengobatan yang efektif untuk memperbaiki gangguan intarksi sosial dan komunikasi pada penderita autistik. Efektifitas yang menjanjikan dari resperidone ini memberikan harapan untuk mengobati anak-anak yang mengalami gangguan perilaku pada autisme.

Article Details

How to Cite
Pinzon, R., Meliala, L., & Sutarni, S. (2007). Telaah kritis terapi risperidone untuk perbaikan perilaku pada gangguan spectrum autistik. Universa Medicina, 26(1), 39–45. https://doi.org/10.18051/UnivMed.2007.v26.39-45
Issue
Vol. 26 No. 1 (2007)
Section
Review Article

The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.

References

Herman A. Neurobiological insights into infantile autism. In: The Harvard brain. Spring; 1996. p. 19-25. Available at: http://www.hcs.harvard.edu/~husn/BRAIN/vol3/contents.html. Accessed April 1, 2006.

Rapin I. Autism: current concept. N Engl J Med 1997; 337: 97-104.

Perry P, Kuperman S. Pediatric psychopharmacology: autism, clinical psychopharmacology Seminar. University of Iowa ; 2003.

Guyatt GH, Sackett DL, Cook DJ. How to use an article about therapy and prevention. JAMA 1995; 27: 59-63.

Dixon RA, Munro JF, Silcocks PB. The evidence based medicine: critical appraisal for clinical problem solving. Oxford: Read Educational and Professional Publishing Ltd. Oxford; 1997.

SIGN. Level of evidence and recommendation. Scotish Intercollegiate Guideline Network, 2001. Available at: http://www.sign.ac.uk. Accessed April 7, 2006.

McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH, et al. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Ach Gen Psychiatry 1998; 53: 633-41.

Masi A, Cosenza A, Mucci M, De Vito G. Risperidone monotherapy in preschool children with pervasive developmental disorders. J Child Neurol 2001; 16: 395-400.

McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. N Eng J Med 2002; 347: 314-1.

Research units on pediatric psychopharmacology autism network. Risperidone treatment of autistic disorder: longer term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005; 162:1361-9.

McDougle MJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, et al. Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry 2005; 162: 1142-8.

Reyes M, Buitelaar J, Toren P, Augustyns I. A randomized, double blind, placebo controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorder. Am J Psychiatry 2006; 163:402-10.

Findling RL, Aman MG, Eerdekens M. Long term, open label study of risperidone in children with severe disruptive behaviors and below average IQ. Am J Psychiatry 2004; 161: 1677-84.

Aman MG, Smedt GD, Derivan A, Lyons B. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1337-46.

Nestler EJ, Hyman SE, Malenka RC. Molecular neuropharmacology: a foundation for clinical neuroscience. New York: McGraw-Hill Companies; 2001.

Jones HM, Pilowsky LS. Dopamine and antipsychotic drug action revisited. Br J Psychiatry 2002; 181: 271-5.

Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114: 634-41.

Turgay A, Binder C, Snyder R, Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002; 110.